Evidence map›Paper›PMID 28926637›Full record

ArticlePloS one2017

Selective cytotoxicity of the anti-diabetic drug, metformin, in glucose-deprived chicken DT40 cells.

Kei Kadoda, Takahito Moriwaki, Masataka Tsuda, Hiroyuki Sasanuma, Masamichi Ishiai, Minoru Takata, Hiroshi Ide, Shin-Ichiro Masunaga, Shunichi Takeda, Keizo Tano

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Kei KadodaDivision of Radiation Life Science, Research Reactor Institute, Kyoto University, Kumatori, Osaka, Japan.
Takahito MoriwakiDivision of Radiation Life Science, Research Reactor Institute, Kyoto University, Kumatori, Osaka, Japan.
Masataka TsudaDepartment of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroyuki SasanumaDepartment of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masamichi IshiaiDepartment of Late Effects Studies, Radiation Biology Center, Kyoto University, Kyoto, Japan.
Minoru TakataDepartment of Late Effects Studies, Radiation Biology Center, Kyoto University, Kyoto, Japan.
Hiroshi IdeDepartment of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Higashi-Hiroshima, Japan.
Shin-Ichiro MasunagaDivision of Radiation Life Science, Research Reactor Institute, Kyoto University, Kumatori, Osaka, Japan.
Shunichi TakedaDepartment of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Keizo TanoDivision of Radiation Life Science, Research Reactor Institute, Kyoto University, Kumatori, Osaka, Japan.ORCID http://orcid.org/0000-0003-3900-0035
Kyoto University · JPKyoto University Research Reactor Institute · JPHiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metformin is a biguanide drug that is widely used in the treatment of diabetes. Epidemiological studies have indicated that metformin exhibits anti-cancer activity. However, the molecular mechanisms underlying this activity currently remain unclear. We hypothesized that metformin is cytotoxic in a tumor-specific environment such as glucose deprivation and/or low oxygen (O2) tension. We herein demonstrated that metformin was highly cytotoxic under glucose-depleted, but not hypoxic (2% O2) conditions. In order to elucidate the underlying mechanisms of this selective cytotoxicity, we treated exposed DNA repair-deficient chicken DT40 cells with metformin under glucose-depleted conditions and measured cellular sensitivity. Under glucose-depleted conditions, metformin specifically killed fancc and fancl cells that were deficient in FANCC and FANCL proteins, respectively, which are involved in DNA interstrand cross-link repair. An analysis of chromosomal aberrations in mitotic chromosome spreads revealed that a clinically relevant concentration of metformin induced DNA double-strand breaks (DSBs) in fancc and fancl cells under glucose-depleted conditions. In summary, metformin induced DNA damage under glucose-depleted conditions and selectively killed cells. This metformin-mediated selective toxicity may suppress the growth of malignant tumors that are intrinsically deprived of glucose.

Indexed as

AnimalsCell LineCell SurvivalChickensChromosome AberrationsDNA Breaks, Double-StrandedDNA RepairGlucoseHypoglycemic AgentsMetforminOxygenGlucoseHypoglycemic AgentsMetforminOxygen

Identifiers

PMID28926637
PMCPMC5605006
OpenAlexW2755630777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.